# Rhythm Pharmaceuticals, Inc.: financial statements, quarterly

RYTM · Nasdaq · CIK 1649904 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/rytm.md) · [Financials](/companies/rytm/financials.md) · [Filings](/companies/rytm/filings.md) · [Insiders](/companies/rytm/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/rytm/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [22.5](/filings/0001558370-24-014532.md) | [24.2 d](/filings/0001628280-26-012399.md) | [26.0](/filings/0001558370-25-006765.md) | [29.1](/filings/0001558370-25-010302.md) | [33.3](/filings/0001104659-25-106264.md) | [41.8 d](/filings/0001628280-26-012399.md) | [32.7](/filings/0001628280-26-030549.md) | [48.5](/filings/0001628280-26-052533.md) | [51.3](/filings/0001104659-25-106264.md) | [57.3 d](/filings/0001628280-26-012399.md) | [60.1](/filings/0001628280-26-030549.md) | [71.3](/filings/0001628280-26-052533.md) |
| Cost of revenue | $m | [2.4](/filings/0001558370-24-014532.md) | [3.2 d](/filings/0001628280-26-012399.md) | [2.8](/filings/0001558370-25-006765.md) | [2.9](/filings/0001558370-25-010302.md) | [3.8](/filings/0001104659-25-106264.md) | [3.8 d](/filings/0001628280-26-012399.md) | [3.6](/filings/0001628280-26-030549.md) | [5.5](/filings/0001628280-26-052533.md) | [5.5](/filings/0001104659-25-106264.md) | [4.8 d](/filings/0001628280-26-012399.md) | [7.2](/filings/0001628280-26-030549.md) | [8.9](/filings/0001628280-26-052533.md) |
| Research and development | $m | [33.6](/filings/0001558370-24-014532.md) | [29.9 d](/filings/0001628280-26-012399.md) | [129](/filings/0001558370-25-006765.md) | [30.2](/filings/0001558370-25-010302.md) | [37.9](/filings/0001104659-25-106264.md) | [41.2 d](/filings/0001628280-26-012399.md) | [37.0](/filings/0001628280-26-030549.md) | [42.3](/filings/0001628280-26-052533.md) | [46.0](/filings/0001104659-25-106264.md) | [42.0 d](/filings/0001628280-26-012399.md) | [41.7](/filings/0001628280-26-030549.md) | [43.4](/filings/0001628280-26-052533.md) |
| Selling, general and administrative | $m | [30.5](/filings/0001558370-24-014532.md) | [32.4 d](/filings/0001628280-26-012399.md) | [34.4](/filings/0001558370-25-006765.md) | [36.4](/filings/0001558370-25-010302.md) | [35.4](/filings/0001104659-25-106264.md) | [38.1 d](/filings/0001628280-26-012399.md) | [39.1](/filings/0001628280-26-030549.md) | [45.9](/filings/0001628280-26-052533.md) | [52.4](/filings/0001104659-25-106264.md) | [57.5 d](/filings/0001628280-26-012399.md) | [63.6](/filings/0001628280-26-030549.md) | [67.4](/filings/0001628280-26-052533.md) |
| Operating income | $m | [(44.0)](/filings/0001558370-24-014532.md) | [(41.3) d](/filings/0001628280-26-012399.md) | [(140)](/filings/0001558370-25-006765.md) | [(40.5)](/filings/0001558370-25-010302.md) | [(43.9)](/filings/0001104659-25-106264.md) | [(41.3) d](/filings/0001628280-26-012399.md) | [(47.0)](/filings/0001628280-26-030549.md) | [(45.3)](/filings/0001628280-26-052533.md) | [(52.7)](/filings/0001104659-25-106264.md) | [(47.1) d](/filings/0001628280-26-012399.md) | [(52.4)](/filings/0001628280-26-030549.md) | [(48.6)](/filings/0001628280-26-052533.md) |
| Interest expense | $m | [3.1](/filings/0001558370-23-018291.md) | [4.6 d](/filings/0001558370-24-002181.md) | [4.8](/filings/0001558370-24-007076.md) | [4.6](/filings/0001558370-25-010302.md) | [5.2](/filings/0001104659-25-106264.md) | [5.4 d](/filings/0001628280-26-012399.md) | [5.4](/filings/0001628280-26-030549.md) | [5.8](/filings/0001628280-26-052533.md) | [4.7](/filings/0001104659-25-106264.md) | [4.6 d](/filings/0001628280-26-012399.md) | [4.6](/filings/0001628280-26-030549.md) | [4.5](/filings/0001628280-26-052533.md) |
| Income tax | $m | [0.4](/filings/0001558370-24-014532.md) | [0.2 d](/filings/0001628280-26-012399.md) | [0.3](/filings/0001558370-25-006765.md) | [0.5](/filings/0001558370-25-010302.md) | [(0.3)](/filings/0001104659-25-106264.md) | [(0.1) d](/filings/0001628280-26-012399.md) | [0.1](/filings/0001628280-26-030549.md) | [0.3](/filings/0001628280-26-052533.md) | [0.1](/filings/0001104659-25-106264.md) | [(0.0) d](/filings/0001628280-26-012399.md) | [0.5](/filings/0001628280-26-030549.md) | [0.4](/filings/0001628280-26-052533.md) |
| Net income | $m | [(44.2)](/filings/0001558370-24-014532.md) | [(41.6) d](/filings/0001628280-26-012399.md) | [(141)](/filings/0001104659-25-106264.md) | [(32.3)](/filings/0001104659-25-106264.md) | [(43.6)](/filings/0001104659-25-106264.md) | [(43.3) d](/filings/0001628280-26-012399.md) | [(49.5)](/filings/0001628280-26-052533.md) | [(46.6)](/filings/0001628280-26-052533.md) | [(52.9)](/filings/0001104659-25-106264.md) | [(47.5) d](/filings/0001628280-26-012399.md) | [(55.6)](/filings/0001628280-26-052533.md) | [(49.3)](/filings/0001628280-26-052533.md) |
| Diluted EPS | $ per share | [(0.76)](/filings/0001558370-24-014532.md) | not reported | [(2.35)](/filings/0001558370-25-006765.md) | [(0.55)](/filings/0001558370-25-010302.md) | [(0.73)](/filings/0001104659-25-106264.md) | not reported | [(0.81)](/filings/0001628280-26-030549.md) | [(0.75)](/filings/0001628280-26-052533.md) | [(0.82)](/filings/0001104659-25-106264.md) | not reported | [(0.83)](/filings/0001628280-26-030549.md) | [(0.73)](/filings/0001628280-26-052533.md) |
| Basic EPS | $ per share | [(0.76)](/filings/0001558370-24-014532.md) | not reported | [(2.35)](/filings/0001558370-25-006765.md) | [(0.55)](/filings/0001558370-25-010302.md) | [(0.73)](/filings/0001104659-25-106264.md) | not reported | [(0.81)](/filings/0001628280-26-030549.md) | [(0.75)](/filings/0001628280-26-052533.md) | [(0.82)](/filings/0001104659-25-106264.md) | not reported | [(0.83)](/filings/0001628280-26-030549.md) | [(0.73)](/filings/0001628280-26-052533.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [64.6](/filings/0001558370-23-018291.md) | [60.1](/filings/0001558370-25-001889.md) | [53.4](/filings/0001558370-24-007076.md) | [162](/filings/0001558370-24-011101.md) | [47.5](/filings/0001558370-24-014532.md) | [89.1](/filings/0001628280-26-012399.md) | [106](/filings/0001558370-25-006765.md) | [136](/filings/0001558370-25-010302.md) | [52.1](/filings/0001104659-25-106264.md) | [54.3](/filings/0001628280-26-052533.md) | [62.1](/filings/0001628280-26-030549.md) | [65.6](/filings/0001628280-26-052533.md) |
| Current assets | $m | [329](/filings/0001558370-23-018291.md) | [308](/filings/0001558370-25-001889.md) | [236](/filings/0001558370-24-007076.md) | [357](/filings/0001558370-24-011101.md) | [340](/filings/0001558370-24-014532.md) | [374](/filings/0001628280-26-012399.md) | [369](/filings/0001558370-25-006765.md) | [361](/filings/0001558370-25-010302.md) | [495](/filings/0001104659-25-106264.md) | [467](/filings/0001628280-26-052533.md) | [430](/filings/0001628280-26-030549.md) | [427](/filings/0001628280-26-052533.md) |
| Total assets | $m | [354](/filings/0001558370-23-018291.md) | [333](/filings/0001558370-25-001889.md) | [259](/filings/0001558370-24-007076.md) | [382](/filings/0001558370-24-011101.md) | [364](/filings/0001558370-24-014532.md) | [392](/filings/0001628280-26-012399.md) | [387](/filings/0001558370-25-006765.md) | [373](/filings/0001558370-25-010302.md) | [507](/filings/0001104659-25-106264.md) | [480](/filings/0001628280-26-052533.md) | [442](/filings/0001628280-26-030549.md) | [437](/filings/0001628280-26-052533.md) |
| Current liabilities | $m | [50.1](/filings/0001558370-23-018291.md) | [55.2](/filings/0001558370-25-001889.md) | [54.2](/filings/0001558370-24-007076.md) | [54.7](/filings/0001558370-24-011101.md) | [97.6](/filings/0001558370-24-014532.md) | [116](/filings/0001628280-26-012399.md) | [112](/filings/0001558370-25-006765.md) | [129](/filings/0001558370-25-010302.md) | [104](/filings/0001104659-25-106264.md) | [106](/filings/0001628280-26-052533.md) | [103](/filings/0001628280-26-030549.md) | [124](/filings/0001628280-26-052533.md) |
| Total liabilities | $m | [157](/filings/0001558370-23-018291.md) | [163](/filings/0001558370-25-001889.md) | [197](/filings/0001558370-24-007076.md) | [202](/filings/0001558370-24-011101.md) | [211](/filings/0001558370-24-014532.md) | [228](/filings/0001628280-26-012399.md) | [224](/filings/0001558370-25-006765.md) | [239](/filings/0001558370-25-010302.md) | [211](/filings/0001104659-25-106264.md) | [210](/filings/0001628280-26-052533.md) | [205](/filings/0001628280-26-030549.md) | [220](/filings/0001628280-26-052533.md) |
| Long-term debt | $m | not reported | [106](/filings/0001558370-25-001889.md) | not reported | not reported | not reported | [108](/filings/0001628280-26-012399.md) | [108](/filings/0001558370-25-006765.md) | [106](/filings/0001558370-25-010302.md) | [103](/filings/0001104659-25-106264.md) | [101](/filings/0001628280-26-052533.md) | [98.3](/filings/0001628280-26-030549.md) | [93.4](/filings/0001628280-26-052533.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | [1.5](/filings/0001628280-26-012399.md) | [1.6](/filings/0001558370-25-006765.md) | [3.8](/filings/0001558370-25-010302.md) | [5.6](/filings/0001104659-25-106264.md) | [7.3](/filings/0001628280-26-052533.md) | [10.1](/filings/0001628280-26-030549.md) | [12.7](/filings/0001628280-26-052533.md) |
| Shareholders' equity | $m | [197](/filings/0001558370-24-014532.md) | [170](/filings/0001628280-26-012399.md) | [61.6](/filings/0001104659-25-106264.md) | [39.3](/filings/0001104659-25-106264.md) | [11.2](/filings/0001104659-25-106264.md) | [21.7](/filings/0001628280-26-052533.md) | [18.9](/filings/0001628280-26-052533.md) | [(11.9)](/filings/0001628280-26-052533.md) | [149](/filings/0001104659-25-106264.md) | [139](/filings/0001628280-26-052533.md) | [123](/filings/0001628280-26-052533.md) | [103](/filings/0001628280-26-052533.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(29.3) d](/filings/0001558370-24-014532.md) | [(29.4) d](/filings/0001628280-26-012399.md) | [(40.7)](/filings/0001558370-25-006765.md) | [(29.1) d](/filings/0001558370-25-010302.md) | [(25.2) d](/filings/0001104659-25-106264.md) | [(18.8) d](/filings/0001628280-26-012399.md) | [(40.4)](/filings/0001628280-26-030549.md) | [(23.3) d](/filings/0001628280-26-052533.md) | [(26.6) d](/filings/0001104659-25-106264.md) | [(25.4) d](/filings/0001628280-26-012399.md) | [(44.2)](/filings/0001628280-26-030549.md) | [(9.2) d](/filings/0001628280-26-052533.md) |
| Capital expenditure | $m | [0.0 d](/filings/0001558370-24-014532.md) | [(0.0) d](/filings/0001628280-26-012399.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [51.4](/filings/0001558370-23-018291.md) | [56.7](/filings/0001558370-23-007675.md) | [56.9](/filings/0001558370-24-011101.md) | [57.9](/filings/0001558370-24-014532.md) | [60.1](/filings/0001558370-25-006765.md) | [61.0](/filings/0001558370-25-010302.md) | [61.2](/filings/0001104659-25-106264.md) | [63.1](/filings/0001628280-26-030549.md) | [63.7](/filings/0001628280-26-052533.md) | [66.3](/filings/0001104659-25-106264.md) | [68.0](/filings/0001628280-26-030549.md) | [68.6](/filings/0001628280-26-052533.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 68,852,082 at 2026-08-01, from the cover of the [10-Q filed 2026-08-04](/filings/0001628280-26-052533.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.